Connect with us

Technology

India shines at London Valves 2024: Meril’s groundbreaking leap in heart valve innovation ‘Myval Octapro THV’ showcased at GISE 2024 and PCR London Valves

Published

on

VAPI, India, Nov. 27, 2024 /PRNewswire/ — Meril Life Sciences, a leading global med-tech company specializing in cardiovascular and structural heart solutions, marked a significant milestone with the launch of its Myval Octapro Transcatheter Heart Valve (THV) at GISE 2024 (National Congress of the Italian Society of Interventional Cardiology) and PCR London Valves 2024. These esteemed scientific events provided an ideal platform for Meril to showcase its commitment to advancing structural heart care.

The Myval THV series, known for its innovative contributions to transcatheter aortic valve replacement (TAVR) procedures, continues to set new benchmarks with the Myval Octapro THV. This latest iteration introduces low frame foreshortening, enhancing operator control and enabling precise deployment for improved procedural predictability. Additionally, its comprehensive size matrix, which includes conventional, intermediate, and extra-large valve sizes, ensures optimal valve selection tailored to diverse patient anatomies.

Speaking on this achievement, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, stated: “The positive reception of the Myval Octapro THV at these global platforms underscores our commitment to delivering cutting-edge solutions for severe aortic stenosis. We are proud to collaborate with clinicians worldwide in advancing TAVR technology and improving patient outcomes through innovation.”

At PCR London Valves 2024, Meril presented key findings from the LANDMARK trial subset analysis and comparative studies, further establishing the safety and efficacy of the Myval Transcatheter Heart Valve (THV) series. Published in EuroIntervention Journal, the findings confirmed the Myval THV’s non-inferiority to both Sapien and Evolut valve series at 30 days post-implantation, solidifying its position as a reliable solution for structural heart interventions.

The results highlighted comparable composite safety and effectiveness outcomes between Myval and Sapien (24.7% vs. 24.1%), with Myval demonstrating a lower rate of permanent pacemaker implantation (15.0% vs. 17.3%) and superior hemodynamic performance. Similarly, the Myval THV series performed on par with Evolut in composite endpoints (24.7% vs. 30%), while showing advantages in reducing pacemaker implantation rates and moderate/severe valve regurgitation. Effective orifice areas were also comparable between 26 and 29 mm of Myval THV series and Evolut THV series, underscoring its strong performance in key clinical measures.

The conference also featured the unveiling of the COMPARE-TAVI trial results. Presented by Prof. Henrik Nissen on behalf of the COMPARE-TAVI investigators, this first-of-its-kind randomized controlled trial directly compared the Myval THV series with the Sapien THV series in a real-world, all-comers population.

Key Findings from the COMPARE-TAVI Trial:

Non-Inferiority Demonstrated: The Myval THV series met the non-inferiority criteria for the composite primary endpoint (death, stroke, moderate/severe aortic regurgitation, and valve deterioration) at one year, with comparable rates to the Sapien THV series (13.8% vs. 13.0%, p = 0.02).Reduced Patient-Prosthesis Mismatch (PPM): Myval THV exhibited a significantly lower incidence of PPM compared to the Sapien series (17.5% vs. 28.6%), a critical factor for long-term valve performance and patient outcomes.

Meril acknowledges the invaluable contributions of clinicians, partners, and patients in achieving this milestone. With the launch of the Myval Octapro THV, Meril continues its mission of improving lives through pioneering structural heart care solutions.

About Meril Life Sciences

Meril is a leading global medical device manufacturing company based in India that has been pivotal in establishing India as a leader in the global medical devices industry. The company’s strong focus on research and development (R&D) and commitment to quality have allowed it to offer cutting-edge medtech solutions in more than 135 countries. Additionally, Meril has a large presence in India with wholly-owned subsidiaries in the USA, UK, Europe, Middle East, Africa, Brazil, South America, Australia & Asia.

With its strong commitment to innovation and quality, Meril has transformed healthcare in India and created significant footprints across the globe. Through global partnerships and the use of advanced technology, the company prioritizes quality and adherence to international standards, fostering a thriving R&D environment. Meril’s efforts have effectively established India as a center for medical device innovation and production.

For further information, please write to: media@merillife.com 

Photo: https://mma.prnewswire.com/media/2568554/OCTAPRO.jpg
Logo: https://mma.prnewswire.com/media/2561843/Meril_Life_Sciences_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/india-shines-at-london-valves-2024-merils-groundbreaking-leap-in-heart-valve-innovation-myval-octapro-thv-showcased-at-gise-2024-and-pcr-london-valves-302317427.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

AIXI Investors Have Opportunity to Lead Xiao-I Corporation Securities Fraud Lawsuit

Published

on

By

BENSALEM, Pa., Nov. 27, 2024 /PRNewswire/ –Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Xiao-I Corporation (“Xiao-I” or the “Company”) (NASDAQ: AIXI).

Class Period: March 9, 2023July 12, 2024

Lead Plaintiff Deadline: December 16, 2024

Investors suffering losses on their Xiao-I investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 215-638-4847 or by email to howardsmith@howardsmithlaw.com.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) Defendants had downplayed the true scope and severity of risks that Xiao-I faced due to certain of its Chinese shareholders’ non-compliance with Circular 37 Registration, including the Company’s inability to use Offering proceeds for intended business purposes; (2) Xiao-I failed to comply with GAAP in preparing its financial statements; (3) Defendants overstated Xiao-I’s efforts to remediate material weaknesses in the Company’s financial controls; (4) Xiao-I was forced to incur significant R&D expenses to effectively compete in the AI industry; (5) Xiao-I downplayed the significant negative impact that such expenses would have on the Company’s business and financial results; (6) accordingly, Xiao-I overstated its AI capabilities, R&D resources, and overall ability to compete in the AI market; (7) as a result of all the foregoing, there was a substantial likelihood that Xiao-I would fail to comply with the NASDAQ’s Minimum Bid Price Requirement; and (8) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847 or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

View original content:https://www.prnewswire.com/news-releases/aixi-investors-have-opportunity-to-lead-xiao-i-corporation-securities-fraud-lawsuit-302317731.html

SOURCE Law Offices of Howard G. Smith

Continue Reading

Technology

WorkFar Robotics Mass Produces Humanoid Robots without Venture Capital

Published

on

By

As robotics investing climbs out of its 2023 slump, humanoid robotics pioneer WorkFar — which has not received any funding from venture capital — is ready to produce at the level of competitors already receiving billions of investment dollars.

SANTA CLARA, Calif., Nov. 27, 2024 /PRNewswire/ — There’s nothing quite like the tenacity of a new company with a unique value proposition that directly addresses the needs of its target customer base. WorkFar Robotics, a business specializing in commercial humanoid service robots for industrial applications, has yet to get on the radar of today’s venture capitalists — but that hasn’t stopped them from reaching the mass-producing stage.

Many companies, particularly those in the robotics industry, are reliant on venture capital, and they can go for years — or even a decade — without turning a profit. Building a cash-flowing robotics company with no investment aside from hard work, creativity, and business acumen is a feat rarely accomplished. Yet WorkFar has managed to achieve the same level of progress as competitors receiving $100 million to over $1 billion in investment funding.

WorkFar’s Business Model: An Autonomous, Remote-operatable Robot for $0 down

WorkFar’s offering is unique in the world of industrial robotics. The industry’s most common business model is to sell an expensive product to a manufacturer and possibly provide some integration services. For companies unable to afford the high price tag, certain robotics manufacturers offer a subscription-based “Robot-as-a-Service.” WorkFar takes this a step further by allowing clients to lease both a robot and a trained, remote operator on a monthly basis without a down payment.

The combination of sophisticated humanoid robot, AI-enhanced programming, and an optional human operator constitutes a turnkey solution for warehouses and manufacturers dealing with aggravating challenges like long-lasting labor shortages, concerns around worker safety and burnout, and issues with efficiency and consistency. Since the optional teleoperator is remote-based, WorkFar can leverage the global workforce to support its customers.

The WorkFar “Syntro” robot uses virtual reality eye tracking and AI algorithms to target and grasp objects at the operator’s direction, and the operator gets feedback on object pick-up through haptic gloves. The robot’s “core logic” is human intelligence, which — despite rapid advances in AI — still can’t be beat.

WorkFar’s Manufacturing Expertise goes back Decades

Although the ‘Syntro’ robot is brand-new, WorkFar’s US based manufacturing facility has over 40 years of experience producing plastic and metal parts for industrial machinery and consumer products. This expertise is now being leveraged to mass produce humanoid robot in-house — an arrangement that cuts out the middleman and leads to more efficient operations. With supply chain issues wreaking havoc on robotics companies’ operations for the past several years, this is a major advantage.

Robotics Investing dipped in 2023, but it’s Coming Back strong with AI and Humanoid Technology

Investment in the robotics industry hit a five-year low last year, particularly in the area of autonomous vehicles (AVs). This was partially a result of a widespread market correction within venture capital investing, but the legislative concerns and negative press surrounding AVs didn’t help. The slump was temporary, however, and robotics venture capital is starting to rise again rapidly, with vertical-specific robotics companies focusing on logistics, security, and medical applications leading the way.

One thing that’s making robotics investing much more appealing is the awe-inspiring takeoff in artificial intelligence capabilities. AI models give robots the capacity to execute complex tasks like grasping unpredictably shaped objects much more smoothly and accurately. Even better, AI allows the robots to learn from each effort, rapidly increasing their accuracy and efficiency over time. Robot vision will gain clarity with improved object detection and image segmentation — essential tools for interacting “intuitively” with the environment.

With a design meant to evoke their maker, humanoid robots are poised to reap the greatest benefits from this rapid growth in AI. They show promise across multiple industries, ranging from manufacturing to healthcare to personal assistance. Once AI’s transformative capabilities became apparent, projections for the humanoid robot market ten years from now shot up from just $6 billion to almost $200 billion — or in some estimates, well over $24 trillion.

Sheer Business Acumen has propelled WorkFar to the point of Mass Production

Although the robotics investment outlook is getting brighter, the recent dip has prompted investors to be more discerning and focus on areas where robotic solutions can make important strides right now. Venture capitalists have seen plenty of technology demos that turn heads; now it’s time to back these up with solid business plans that show real returns on investment. With its robot-as-a-service offering at $0 down payment, this is WorkFar’s strong suit.

Even with rapid AI advances, this model will always benefit from the authority and decision-making power of human intelligence. This is central to WorkFar’s vision: a human-robot team that will unleash a new era of productivity, bringing collaborative efficiency to factories and facilities worldwide. This innovative solution takes into account what other solutions overlook: the fact that true productivity depends on human decision-making and robotic efficiency being intertwined, not isolated.

This vision is what has enabled WorkFar to grow on its own revenue in an industry that usually requires millions or even billions of dollars in venture capital. No longer a startup, this company has now pushed into a higher corporate level of investment based on business acumen alone. With a market-ready product that can be manufactured in WorkFar’s own factory, the humanoid robotics pioneer is stronger because it does not rely on venture capital. 

To inquire, contact us via www.WorkFar.com now!

Contact: info@workfar.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/workfar-robotics-mass-produces-humanoid-robots-without-venture-capital-302317854.html

SOURCE WorkFar Inc

Continue Reading

Technology

ASML Investors Have Opportunity to Lead ASML Holding N.V. Securities Fraud Lawsuit

Published

on

By

LOS ANGELES, Nov. 27, 2024 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ASML Holding N.V. (“ASML” or the “Company”) (NASDAQ: ASML).

Class Period: January 24, 2024October 15, 2024

Lead Plaintiff Deadline: January 13, 2025

If you are a shareholder who suffered a loss, click here to participate.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) the issues being faced by suppliers, like ASML, in the semiconductor industry were much more severe than Defendants had indicated to investors; (2) the pace of recovery of sales in the semiconductor industry was much slower than Defendants had publicly acknowledged; (3) Defendants had created the false impression that they possessed reliable information pertaining to customer demand and anticipated growth, while also downplaying risk from macroeconomic and industry fluctuations, as well as stronger regulations restricting the export of semiconductor technology, including the products that ASML sells; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com.  If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/asml-investors-have-opportunity-to-lead-asml-holding-nv-securities-fraud-lawsuit-302317739.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

Continue Reading

Trending